Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia-Reference-Cited by-同舟云学术

Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia

Published:2014-04-04 Issue:12 Volume:120 Page:1838-1846
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Giagounidis Aristoteles¹,Mufti Ghulam J.²,Fenaux Pierre³,Sekeres Mikkael A.⁴,Szer Jeffrey⁵,Platzbecker Uwe⁶,Kuendgen Andrea⁷,Gaidano Gianluca⁸,Wiktor‐Jedrzejczak Wieslaw⁹,Hu Kuolung¹⁰,Woodard Paul¹⁰,Yang Allen S.¹⁰,Kantarjian Hagop M.¹¹

Affiliation:

1. Clinic for Oncology, Hematology, and Palliative MedicineMarien Hospital DusseldorfDusseldorf Germany

2. Department of Haemato‐Oncology, King's College LondonLondon United Kingdom

3. Clinical Hematology Service, Avicenne HospitalUniversity of Paris XIIIBobigny France

4. Leukemia ProgramCleveland Clinic Taussig Cancer InstituteCleveland Ohio

5. Clinical HematologyRoyal Melbourne HospitalMelbourne Australia

6. Medical Clinic and Polyclinic IUniversity Hospital Carl Gustav Carus DresdenDresden Germany

7. Medical Clinic and Polyclinic A, University HospitalHeinrich‐Heine University of DusseldorfDusseldorf Germany

8. Division of Hematology, Department of Translational MedicineAmedeo Avogadro University of Eastern PiedmontNovara Italy

9. Independent Public Central Hospital ClinicMedical University of WarsawWarsaw Poland

10. Amgen Inc.Thousand Oaks California

11. Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas

Funder

Amgen Corporation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.28663

Reference28 articles.

1. A prognostic score for patients with lower risk myelodysplastic syndrome

2. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

3. The incidence and impact of thrombocytopenia in myelodysplastic syndromes

4. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

5. Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How I diagnose and treat thrombocytopenia in geriatric patients;Blood;2024-01-18

2. High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study;Hematology;2023-12-29

3. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS);Journal of Clinical Oncology;2023-10-01

4. Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia;Journal of Clinical Oncology;2023-10-01

5. Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms;Future Oncology;2023-09